Disappointing Data Prompts GSK to Drop Cough Drug Development
GSK stops development of chronic cough drug camlipixant after mixed Phase 3 results; continue testing it for irritable bowel disease.
Why It Matters
GSK decided to stop making a cough medicine because test results weren't good enough, but they'll keep testing it for a different sickness. This shows the company is being careful about which medicines are worth finishing.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.